Maricar F Malinis1, Shu Chen2, Heather G Allore2, Vincent J Quagliarello1. 1. Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, USA. 2. Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine, New Haven, USA.
Abstract
BACKGROUND: Since 2002, the Model of End Stage Liver Disease (MELD) score has been the basis of the liver transplant (LT) allocation system. Among older adult LT recipients, short-term outcomes in the MELD era were comparable to the pre-MELD era, but long-term outcomes remain unclear. MATERIAL AND METHODS: This is a retrospective cohort study using the UNOS data on patients age ≥ 50 years who underwent primary LT from February 27, 2002 until October 31, 2011. RESULTS: A total of 35,686 recipients met inclusion criteria. The cohort was divided into 5-year interval age groups. Five-year over-all survival rates for ages 50-54, 55-59, 60-64, 65-69, and 70+ were 72.2%, 71.6%, 69.5%, 65.0%, and 57.5%, respectively. Five-year graft survival rates after adjusting for death as competing risk for ages 50-54, 55-59,60-64, 65-69 and 70+ were 85.8%, 87.3%, 89.6%, 89.1% and 88.9%, respectively. By Cox proportional hazard modeling, age ≥ 60, increasing MELD, donor age ≥ 60, hepatitis C, hepatocellular carcinoma (HCC), dialysis and impaired pre-transplant functional status (FS) were associated with increased 5-year mortality. Using Fine and Gray sub-proportional hazard modeling adjusted for death as competing risk, 5-year graft failure was associated with donor age ≥ 60, increasing MELD, hepatitis C, HCC, and impaired pre-transplant FS. CONCLUSIONS: Among older LT recipients in the MELD era, long-term graft survival after adjusting for death as competing risk was improved with increasing age, while over-all survival was worse. Donor age, hepatitis C, and pre-transplant FS represent potentially modifiable risk factors that could influence long-term graft and patient survival.
BACKGROUND: Since 2002, the Model of End Stage Liver Disease (MELD) score has been the basis of the liver transplant (LT) allocation system. Among older adult LT recipients, short-term outcomes in the MELD era were comparable to the pre-MELD era, but long-term outcomes remain unclear. MATERIAL AND METHODS: This is a retrospective cohort study using the UNOS data on patients age ≥ 50 years who underwent primary LT from February 27, 2002 until October 31, 2011. RESULTS: A total of 35,686 recipients met inclusion criteria. The cohort was divided into 5-year interval age groups. Five-year over-all survival rates for ages 50-54, 55-59, 60-64, 65-69, and 70+ were 72.2%, 71.6%, 69.5%, 65.0%, and 57.5%, respectively. Five-year graft survival rates after adjusting for death as competing risk for ages 50-54, 55-59,60-64, 65-69 and 70+ were 85.8%, 87.3%, 89.6%, 89.1% and 88.9%, respectively. By Cox proportional hazard modeling, age ≥ 60, increasing MELD, donor age ≥ 60, hepatitis C, hepatocellular carcinoma (HCC), dialysis and impaired pre-transplant functional status (FS) were associated with increased 5-year mortality. Using Fine and Gray sub-proportional hazard modeling adjusted for death as competing risk, 5-year graft failure was associated with donor age ≥ 60, increasing MELD, hepatitis C, HCC, and impaired pre-transplant FS. CONCLUSIONS: Among older LT recipients in the MELD era, long-term graft survival after adjusting for death as competing risk was improved with increasing age, while over-all survival was worse. Donor age, hepatitis C, and pre-transplant FS represent potentially modifiable risk factors that could influence long-term graft and patient survival.
Authors: H U Meier-Kriesche; A Ojo; J Hanson; D Cibrik; K Lake; L Y Agodoa; A Leichtman; B Kaplan Journal: Transplantation Date: 2000-03-15 Impact factor: 4.939
Authors: Robert S Brown; K Shiva Kumar; Mark W Russo; Milan Kinkhabwala; Dianne L Rudow; Patricia Harren; Steven Lobritto; Jean C Emond Journal: Liver Transpl Date: 2002-03 Impact factor: 5.799
Authors: J S Rumsfeld; S MaWhinney; M McCarthy; A L Shroyer; C B VillaNueva; M O'Brien; T E Moritz; W G Henderson; F L Grover; G K Sethi; K E Hammermeister Journal: JAMA Date: 1999-04-14 Impact factor: 56.272
Authors: J Busquets; X Xiol; J Figueras; E Jaurrieta; J Torras; E Ramos; A Rafecas; J Fabregat; C Lama; L Ibañez; L Llado; J M Ramon Journal: Transplantation Date: 2001-06-27 Impact factor: 4.939
Authors: M Berenguer; L Ferrell; J Watson; M Prieto; M Kim; M Rayón; J Córdoba; A Herola; N Ascher; J Mir; J Berenguer; T L Wright Journal: J Hepatol Date: 2000-04 Impact factor: 25.083
Authors: M F Levy; P S Somasundar; L W Jennings; G J Jung; E P Molmenti; C G Fasola; R M Goldstein; T A Gonwa; G B Klintmalm Journal: Ann Surg Date: 2001-01 Impact factor: 12.969
Authors: Xavier Forns; Montserrat García-Retortillo; Trinidad Serrano; Anna Feliu; Francisco Suarez; Manuel de la Mata; Juan Carlos García-Valdecasas; Miquel Navasa; Antoni Rimola; Juan Rodés Journal: J Hepatol Date: 2003-09 Impact factor: 25.083
Authors: Paul H Hayashi; Lisa Forman; Tracy Steinberg; Thomas Bak; Michael Wachs; Marcelo Kugelmas; Gregory T Everson; Igal Kam; James F Trotter Journal: Liver Transpl Date: 2003-07 Impact factor: 5.799
Authors: J Ignacio Herrero; Juan Felipe Lucena; Jorge Quiroga; Bruno Sangro; Fernando Pardo; Fernando Rotellar; Javier Alvárez-Cienfuegos; Jesús Prieto Journal: Am J Transplant Date: 2003-11 Impact factor: 8.086
Authors: Jennifer C Lai; Christopher J Sonnenday; Elliot B Tapper; Andres Duarte-Rojo; Michael A Dunn; William Bernal; Elizabeth J Carey; Srinivasan Dasarathy; Binita M Kamath; Matthew R Kappus; Aldo J Montano-Loza; Shunji Nagai; Puneeta Tandon Journal: Am J Transplant Date: 2019-05-08 Impact factor: 8.086